$CCEL
CRYO CELL INTERNATIONAL INC

2021 Q3 Form 10-Q Financial Statement

#000156459021050960 Filed on October 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $7.504M $8.114M $7.872M
YoY Change -7.53% -1.33% -3.15%
Cost Of Revenue $2.459M $2.360M $2.481M
YoY Change 4.18% -8.84% -5.62%
Gross Profit $5.045M $5.754M $5.391M
YoY Change -12.33% 2.13% -1.97%
Gross Profit Margin 67.23% 70.91% 68.49%
Selling, General & Admin $3.494M $3.376M $3.559M
YoY Change 3.49% -5.08% -2.45%
% of Gross Profit 69.26% 58.67% 66.01%
Research & Development $10.00K $1.248K $9.821K
YoY Change 701.28% -48.85% 98.12%
% of Gross Profit 0.2% 0.02% 0.18%
Depreciation & Amortization $320.7K $93.82K $95.11K
YoY Change 241.81% -2.43% -8.04%
% of Gross Profit 6.36% 1.63% 1.76%
Operating Expenses $3.448M $3.377M $3.568M
YoY Change 2.11% -5.11% -2.31%
Operating Profit $1.596M $2.480M $1.752M
YoY Change -35.64% 24.44% 252.86%
Interest Expense $335.9K $338.7K $365.4K
YoY Change -0.83% -18.18% -13.89%
% of Operating Profit 21.04% 13.66% 20.85%
Other Income/Expense, Net $30.00 $17.00 -$418.8K
YoY Change 76.47% -100.0% 6.86%
Pretax Income $1.261M $936.0K $1.333M
YoY Change 34.74% -42.04% 1174.52%
Income Tax $404.7K $151.6K $380.0K
% Of Pretax Income 32.09% 16.19% 28.5%
Net Earnings $856.5K $784.5K $953.3K
YoY Change 9.18% -29.72% 1676.2%
Net Earnings / Revenue 11.41% 9.67% 12.11%
Basic Earnings Per Share $0.10 $0.10 $0.13
Diluted Earnings Per Share $0.10 $0.10 $0.12
COMMON SHARES
Basic Shares Outstanding 8.452M 7.546M 7.546M
Diluted Shares Outstanding 8.692M 8.179M 8.112M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.775M $8.170M $9.325M
YoY Change -4.84% -0.53% 27.59%
Cash & Equivalents $7.701M $8.108M $8.420M
Short-Term Investments $74.12K $62.72K $905.4K
Other Short-Term Assets $862.7K $287.0K $241.9K
YoY Change 200.56% 10.41% -13.04%
Inventory $834.0K $1.203M $1.054M
Prepaid Expenses $599.4K $684.9K
Receivables $5.449M $6.504M $5.974M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.92M $16.76M $17.28M
YoY Change -10.99% 5.3% 15.18%
LONG-TERM ASSETS
Property, Plant & Equipment $4.021M $1.664M $1.739M
YoY Change 141.64% -5.95% -0.52%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $1.199M $1.215M
YoY Change -5.51% -5.6%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $36.66M $26.01M $25.82M
YoY Change 40.93% 7.76% 6.97%
Total Long-Term Assets $44.50M $27.68M $27.56M
YoY Change 60.8% 6.83% 6.46%
TOTAL ASSETS
Total Short-Term Assets $14.92M $16.76M $17.28M
Total Long-Term Assets $44.50M $27.68M $27.56M
Total Assets $59.42M $44.44M $44.84M
YoY Change 33.72% 6.25% 9.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $999.1K $900.0K $951.9K
YoY Change 11.02% -11.16% -7.5%
Accrued Expenses $1.954M $1.049M $1.939M
YoY Change 86.29% -23.59% 100.91%
Deferred Revenue $9.326M $9.107M $8.840M
YoY Change 2.41% 3.71% 5.67%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.664M $3.100M $3.100M
YoY Change -14.07% 0.0% 0.0%
Total Short-Term Liabilities $19.86M $14.43M $15.10M
YoY Change 37.64% 1.13% 10.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.598M $4.353M
YoY Change -100.0% -45.52% 205.47%
Other Long-Term Liabilities $34.77M $34.05M $34.72M
YoY Change 2.11% -1.38% -1.83%
Total Long-Term Liabilities $34.77M $34.05M $34.72M
YoY Change 2.11% -1.38% -5.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.86M $14.43M $15.10M
Total Long-Term Liabilities $34.77M $34.05M $34.72M
Total Liabilities $54.63M $48.48M $49.82M
YoY Change 12.68% -0.64% 1.72%
SHAREHOLDERS EQUITY
Retained Earnings -$20.02M -$20.80M
YoY Change -14.04% -14.76%
Common Stock $36.55M $36.38M
YoY Change 1.81% 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $20.56M
YoY Change 5.07% 5.07%
Treasury Stock Shares $6.094M $6.094M
Shareholders Equity $4.799M -$4.036M -$4.983M
YoY Change
Total Liabilities & Shareholders Equity $59.42M $44.44M $44.84M
YoY Change 33.72% 6.25% 9.66%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income $856.5K $784.5K $953.3K
YoY Change 9.18% -29.72% 1676.2%
Depreciation, Depletion And Amortization $320.7K $93.82K $95.11K
YoY Change 241.81% -2.43% -8.04%
Cash From Operating Activities $2.059M $2.052M $822.2K
YoY Change 0.36% -25.18% 55.81%
INVESTING ACTIVITIES
Capital Expenditures -$1.532M -$2.170K -$43.27K
YoY Change 70486.64% -97.8% -87.97%
Acquisitions
YoY Change
Other Investing Activities $0.00 $358.1K
YoY Change -100.0% 35709.0%
Cash From Investing Activities -$1.532M $355.9K -$43.27K
YoY Change -530.36% -465.16% -87.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -775.0K -2.720M -775.0K
YoY Change -71.51% 53.24% 0.0%
NET CHANGE
Cash From Operating Activities 2.059M 2.052M 822.2K
Cash From Investing Activities -1.532M 355.9K -43.27K
Cash From Financing Activities -775.0K -2.720M -775.0K
Net Change In Cash -247.3K -312.0K 3.930K
YoY Change -20.74% -135.85% -100.65%
FREE CASH FLOW
Cash From Operating Activities $2.059M $2.052M $822.2K
Capital Expenditures -$1.532M -$2.170K -$43.27K
Free Cash Flow $3.591M $2.054M $865.5K
YoY Change 74.81% -27.69% -2.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y2M26D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
690347
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-971756
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2272746
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3854911
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3208731
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1134198
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
783960
us-gaap Net Income Loss
NetIncomeLoss
2720713
us-gaap Net Income Loss
NetIncomeLoss
2424771
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7996278
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544124
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8217454
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8137463
us-gaap Profit Loss
ProfitLoss
2720713
us-gaap Profit Loss
ProfitLoss
2424771
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
711905
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
284689
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1032
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-604109
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-169741
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-14352
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-133250
us-gaap Share Based Compensation
ShareBasedCompensation
233869
us-gaap Share Based Compensation
ShareBasedCompensation
450746
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
271460
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
501312
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
47462
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67010
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
211434
ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
197079
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-602187
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
907531
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-98618
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
99169
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-301489
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-237728
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
104999
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
26635
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
24716
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
52103
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
41728
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-469160
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1393462
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-757318
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-206729
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-196939
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3337417
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2799957
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6258619
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5489878
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
708087
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1554004
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52396
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
350000
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5106224
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4228998
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2660319
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1566571
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
161994
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
784467
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4036334
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
450746
us-gaap Net Income Loss
NetIncomeLoss
2424771
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4036334
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7700806
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6660228
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
305691
ccel Payments For Extinguishment Of Revenue Sharing Agreements
PaymentsForExtinguishmentOfRevenueSharingAgreements
1900000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3325000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2324998
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1066290
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
ccel Payment Of Earnout
PaymentOfEarnout
45000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2258710
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8107608
ccel Operating Lease Liability And Right Of Use Asset Due To Adoption Of Asc842
OperatingLeaseLiabilityAndRightOfUseAssetDueToAdoptionOfASC842
562775
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
904691
ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
500000
ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
11315894
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
142167
us-gaap Stock Issued1
StockIssued1
3585172
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4003118
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-142167
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
81297
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
856494
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4798742
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4509295
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
233869
us-gaap Net Income Loss
NetIncomeLoss
2720713
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4798742
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4982795
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
39721777
CY2021Q3 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9326124
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35308468
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2021Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
12678
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
34383
CY2020Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14261
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
37405
CY2021Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
26410
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
72147
CY2020Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
22351
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
68152
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
519541
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5449313
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9326124
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9183450
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
30395653
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27200910
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020Q3 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2021Q3 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
72421
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
19021
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
28066214
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
28939861
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
13482055
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
10144638
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
68152
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
16049
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
450638
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
28361238
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
27955019
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6503550
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32508511
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
13045728
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
10245771
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2021Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-14000
ccel Number Of Units Anticipated To Be Sold Each Year
NumberOfUnitsAnticipatedToBeSoldEachYear
16
ccel Percentage Of Decline In Annual Sales
PercentageOfDeclineInAnnualSales
0.03
CY2021Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
162000
CY2020Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-135000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-133000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;">Product Warranty and Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Program</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.  Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients.  Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, PrepaCyte CB.  Additionally, under the Cryo-Cell Cares<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloablative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company.  The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.  </p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. The Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7545613
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2360324
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1596338
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2480221
CY2021Q3 us-gaap Interest Expense
InterestExpense
335870
CY2020Q3 us-gaap Interest Expense
InterestExpense
338675
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
21569464
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23606976
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6693806
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7503652
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8114358
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2458938
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7344011
us-gaap Operating Income Loss
OperatingIncomeLoss
4826667
us-gaap Operating Income Loss
OperatingIncomeLoss
5481477
us-gaap Interest Expense
InterestExpense
957479
us-gaap Interest Expense
InterestExpense
1069345
CY2021Q3 us-gaap Assets
Assets
59424030
CY2020Q4 us-gaap Assets
Assets
46200094
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021Q3 ccel Inventory Collection Kits
InventoryCollectionKits
34948
CY2020Q4 ccel Inventory Collection Kits
InventoryCollectionKits
33006
CY2021Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2021Q3 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11689863
CY2020Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11991352
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544124
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
25862
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7996278
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1572804
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1181588
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51000
CY2021Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2021Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
12390
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
47462
CY2020Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
20193
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
67012
CY2021Q3 us-gaap Notes Payable
NotesPayable
2683433
CY2020Q4 us-gaap Notes Payable
NotesPayable
6008433
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
19757
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
67219
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
2663676
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2663676
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2841214
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
2663676
us-gaap Interest Expense Debt
InterestExpenseDebt
99294
CY2021Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
12390
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
47462
CY2021Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
38252
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
146756
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
63560
us-gaap Interest Expense Debt
InterestExpenseDebt
254945
CY2020Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
20193
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
67012
CY2020Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
83753
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
321957
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
856494
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
784467
us-gaap Net Income Loss
NetIncomeLoss
2720713
us-gaap Net Income Loss
NetIncomeLoss
2424771
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8452374
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
239957
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
633852
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
221176
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
593339
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8692331
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8179465
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8217454
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8137463
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.94
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
569643
CY2021Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.45
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
501150
CY2021Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.05
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
93380
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
44887
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.00
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
68493
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2021Q1 ccel Lessee Operating Lease Extended Term Of Contract
LesseeOperatingLeaseExtendedTermOfContract
P36M
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
In January 2021, the Company exercised its right to extend a lease for 36 months
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
780070
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P24M
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86549
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
86549
CY2021Q2 ccel Additional Increase To Operating Lease Right Of Use Asset
AdditionalIncreaseToOperatingLeaseRightOfUseAsset
38072
CY2021Q2 ccel Additional Increase To Operating Lease Liabilities
AdditionalIncreaseToOperatingLeaseLiabilities
38072
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
780070
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
992346
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
306817
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
690347
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23632
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
299202
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
82545
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
339182
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
313996
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
295086
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24590
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
58235
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
997164
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
82545
us-gaap Operating Lease Payments
OperatingLeasePayments
229675
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
65754
us-gaap Operating Lease Payments
OperatingLeasePayments
196940
ccel Covid19
Covid19
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Palatino Linotype;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Note 12 – COVID-19</span></p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Palatino Linotype;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (“COVID-19”) outbreak.  The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19.  The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts.  Due to the change in consumer buying patterns as a result of COVID-19, the Company has experienced a decline in new client and public banking sales resulting in a decrease in revenues for the three and nine months ended August 31, 2021 compared to the three and nine months ended August 31, 2020.  While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client and public banking sales.  We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results. </p>
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2020Q4 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0001564590-21-050960-index-headers.html Edgar Link pending
0001564590-21-050960-index.html Edgar Link pending
0001564590-21-050960.txt Edgar Link pending
0001564590-21-050960-xbrl.zip Edgar Link pending
ccel-10q_20210831.htm Edgar Link pending
ccel-10q_20210831_htm.xml Edgar Link completed
ccel-20210831.xsd Edgar Link pending
ccel-20210831_cal.xml Edgar Link unprocessable
ccel-20210831_def.xml Edgar Link unprocessable
ccel-20210831_lab.xml Edgar Link unprocessable
ccel-20210831_pre.xml Edgar Link unprocessable
ccel-ex311_8.htm Edgar Link pending
ccel-ex312_6.htm Edgar Link pending
ccel-ex313_7.htm Edgar Link pending
ccel-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending